Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 168.61M P/E 32.82 EPS this Y -40.00% Ern Qtrly Grth -
Income 15.38M Forward P/E 18.05 EPS next Y -11.10% 50D Avg Chg 6.00%
Sales 226.63M PEG 0.07 EPS past 5Y - 200D Avg Chg 3.00%
Dividend N/A Price/Book 6.52 EPS next 5Y 232.50% 52W High Chg -30.00%
Recommedations 3.00 Quick Ratio 1.34 Shares Outstanding 48.24M 52W Low Chg 74.00%
Insider Own 15.40% ROA 8.10% Shares Float 32.06M Beta 1.30
Inst Own 73.39% ROE 40.02% Shares Shorted/Prior 3.11M/3.29M Price 3.61
Gross Margin 73.44% Profit Margin 6.78% Avg. Volume 216,567 Target Price 4.33
Oper. Margin -5.25% Earnings Date Aug 1 Volume 122,028 Change 1.69%
About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Puma Biotechnology Inc News
05/05/24 Analysts Have Lowered Expectations For Puma Biotechnology, Inc. (NASDAQ:PBYI) After Its Latest Results
05/04/24 Puma Biotechnology First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
05/03/24 Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call Transcript
05/03/24 Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat
05/03/24 Puma Biotechnology Inc (PBYI) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ...
05/02/24 Puma Biotechnology Inc (PBYI) Reports Q1 Financial Results, Misses Analyst Revenue and EPS Forecasts
05/02/24 Puma Biotechnology Reports First Quarter Financial Results
04/29/24 Is Puma Biotechnology, Inc. (NASDAQ:PBYI) A High Quality Stock To Own?
04/26/24 What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
04/18/24 Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
04/08/24 Puma Biotechnology (NASDAQ:PBYI) shareholders have earned a 93% return over the last year
04/03/24 Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/22/24 Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?
03/22/24 Do Puma Biotechnology's (NASDAQ:PBYI) Earnings Warrant Your Attention?
03/20/24 Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
03/05/24 FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
03/04/24 J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer
03/02/24 Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2023 Earnings Call Transcript
03/02/24 Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Could Be 47% Below Their Intrinsic Value Estimate
03/01/24 Q4 2023 Puma Biotechnology Inc Earnings Call
PBYI Chatroom

User Image more_gains Posted - 23 hours ago

1. $PBYI pays Pfizer (Wyeth parent) ~15% royalty rt for WW exclusive patent licenses (incl '314 and '162), meaning they keep ~85% of revenue. 2. $pbyi initiated the suit (implies they knew they would get something) and has contractual rights to recover monetary damages from Pfizer on any award. 3. Why wouldn't pbyi's recovery rate be ~85% (royalty rt paid on infringement awards the same as paid for use)? 4. $107.5M verdict x ~85% recovery = $91M to pbyi 48M sh = +$1.90/pbyi sh $4.10 pbyi pre-verdict 5. $PBYI ~$6 now (plus value on future royalty litigation)? Shout out if dis/agree or drop a question to Puma's IR to elaborate on the recovery rate to Puma on the jury award: (424) 248-6500 [email protected] [email protected] PBYI 2023 10-K showing royalty rt 'low to mid teens' for Pfizer license (meaning PBYI keeps ~85% of revenue) 3/19/24 press release saying 'contractual rights to recovery damages from AstraZeneca in license agreement with Pfizer' (repeated in 5/17/24 release)

User Image Jonnyking Posted - 23 hours ago

$PBYI Not sure why AZN decided to go for a lawsuit trial... They should have listened to me, buying PBYI for 1b to settle the lawsuit... Now they are losing 107m up front(damage before December 2023) and more is coming. The royalty from Tagarisso due to patent violation will be way significant more than 107m.. We should be able to know the percentage of royalty we can collect from AZN.... I will all in next Monday at 4 dollars.... Thanks a lots, short sellers... 5 dollars is the minimum price without winning lawsuit... So, I think we are going to trade at 10 very soon... What a great week

User Image US_Bull Posted - 1 day ago

$PBYI Astra is scheduled in June for additional defenses for invalidation of the two patents but doubt they will succeed. Question is how much of the 108 million goes to Puma for damages and additional royalty and damages for the remainder of the patent lives

User Image US_Bull Posted - 1 day ago

$PBYI How this company has not been BO yet is beyond so primes especially now with the litigation and favorable ruling Auerbach sold previous company same will happen here buying more in weakness monday

User Image chris2931 Posted - 1 day ago

$PBYI https://www.sec.gov/ix?doc=/Archives/edgar/data/0001401667/000143774924017504/pbyi20240517_8k.htm

User Image Richkid Posted - 1 day ago

$PBYI @Jonnyking fuck man. I just sold 40 contracts today.. for $0.20 cents premium. This shit better not go more than $7.50 between now and June 21st. It’s all good though. I have 16k shares left.

User Image Jonnyking Posted - 1 day ago

$PBYI Alan got very excited...."The Court has scheduled a bench trial for June 17-18 and 20, 2024 on AstraZeneca’s remaining equitable defenses of unclean hands, patent misuse, and indefiniteness", unclean hands..., lol, I do think we are definitely close to an end by sometime in June. Alan should now lay off all R&D team, leaving only the sales team, we can gain at least 100m net profit from the rest of the revenue from Neratinib, combining the 200m(my speculation) from AZN, we are sit at 14-16 dollars a share comfortably...

User Image Jonnyking Posted - 1 day ago

$PBYI "PBYI is an exclusive licensee of the '314 and '162 patents under the Pfizer Agreement." Wyeth owns the patents, but it was licensed to PBYI. The damage before 12/31/2023 is 107.5m, they are going to talk about the percentage of royalty after. This is a clear win for PBYI, I do believe majority of the damage will goes to PBYI, PBYI and Pfizer should have agreement while licensed the patent, they should have a percentage ratio, just like Neratinib, PBYI pay royalty to pfizer I think we should be able to see how much royalty we can collect from Tagarisso, the revenue is over 7b this year.... I personally believe we can gain at least 200m, that is like 4 dollars a share right there...So, we are winning,..

User Image Jonnyking Posted - 1 day ago

$PBYI "Further proceedings in the case will be scheduled before the Court to determine the appropriate royalty rate to be applied through the remainder of the term of the patents." 107.5m is paid for the damage till 12/31/2023, more is coming after...So, we are gaining something... 100m at the very least, IMHO....

User Image Jonnyking Posted - 1 day ago

$PBYI Damaging is about 107.5m before December 31 2023 and more might coming after as well.. I believe PBYI and Wyth co-own patent 314 and 162, thus we should get something, 50m, 60m.. let's wait till Alan release an remark The point is we did win the case, not significantly, but it is a win. The infringement is confirmed, but willful infringement https://storage.courtlistener.com/recap/gov.uscourts.ded.76587/gov.uscourts.ded.76587.457.0.pdf

User Image US_Bull Posted - 1 day ago

$PBYI Yeah they are covering AH

User Image Gius_me Posted - 1 day ago

$PBYI oh ok, I did read it. So Wyeth won 107 mln. What does it mean for us? May we recover trial lawyers costs? Or can we get part of the amount?

User Image Gius_me Posted - 1 day ago

$PBYI I’m so sorry guys, i cannot open it. May someone copy paste the content or one important paragraph? 🙏🥹

User Image US_Bull Posted - 1 day ago

$PBYI OPEX today will be up next week.

User Image _www_larval_com_ Posted - 1 day ago

$CTNT 8%[44%] $TUP 7%[36%] $XIN -6%[32%] $PBYI -4%[-7%] $SWIN 3%[23%] most notable movement into the final minutes of trading.

User Image Jonnyking Posted - 1 day ago

$PBYI lol....... 4.1 to 4.97 in 2 minute, and down to 4.1 again... if this is not manipulations....

User Image fatcoin888 Posted - 1 day ago

$PBYI https://seekingalpha.com/news/4108031-puma-biotech-surges-amid-wyeth-victory-in-tagrisso-patent-case?utm_campaign=%7Clogin_now_link&utm_medium=email&utm_source=seeking_alpha

User Image StockRedBaron Posted - 1 day ago

$PBYI C'mon on that news!!!

User Image US_Bull Posted - 1 day ago

$PBYI In with 3930 shares that spike there is something behind it on large volume

User Image Unicorn2020 Posted - 1 day ago

$PBYI Bought 20K shares @ $4.12 today. Now I'm bullish, y'all. LOL.

User Image fastmoneytraderz Posted - 1 day ago

shorted $PBYI 4.75 covered 4.44

User Image Jonnyking Posted - 1 day ago

$PBYI Bought 5000 shares overall today between 4.1 to 4.2... sold 50 June 5 dollars calls for 75 each...average about 3.5... if called away by june, a nice 7.5k profit right there... I have enough free shares for 10 dollars a share...

User Image VrtcIl Posted - 1 day ago

How much more potential do you see on $PBYI? 5? 8? 11? Look for key indicators such as trend strength, support and resistance levels, and potential breakout or reversal patterns. Price: 4.8 Float: 37.1M Short Float: 8.8 % 💰 Dollar Volume: 325.9K ℹ️ USA | Biotechnology

User Image MOMOPro Posted - 1 day ago

Should be hitting slower scanners soon in next 3 min or so. $PBYI

User Image MOMOPro Posted - 1 day ago

$PBYI nice spikey... huge short interest.

User Image mauriz Posted - 1 day ago

$PBYI WTF!

User Image Jonnyking Posted - 1 day ago

$PBYI pure manipulation....

User Image Jonnyking Posted - 1 day ago

$PBYI "ORAL ORDER: On or before June 4, 2024, the respective parties are hereby instructed to submit a joint status report. A 3-day Bench Trial has been scheduled to begin June 17, 2024, at 9:30 a.m. CST in Chicago, Illinois. Ordered by Judge Matthew F Kennelly on 05/16/2024. (vfm)"

User Image Jonnyking Posted - 2 days ago

$PBYI on the one hand, they pin the price down significantly, on the second hand they bought all the 5 dollars calls expires next month for 75 dollars a piece....just impressive bunch of manipulators... Bought 2000 more shares today and sold 20 calls, my average is 3.5 or less for those shares bought today, if those shares is bought by them, I still have over 3k profit...

User Image Cinderella74 Posted - 2 days ago

$PBYI weak as always.

Analyst Ratings
HC Wainwright & Co. Buy May 3, 24
HC Wainwright & Co. Buy Mar 1, 24
HC Wainwright & Co. Buy Feb 13, 24
HC Wainwright & Co. Buy Sep 20, 23
HC Wainwright & Co. Buy Aug 4, 23
HC Wainwright & Co. Buy Jun 5, 23
HC Wainwright & Co. Buy May 5, 23
HC Wainwright & Co. Buy Mar 6, 23
HC Wainwright & Co. Buy Aug 5, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Wong Alvin F Chief Scientific Off.. Chief Scientific Officer Dec 04 Sell 3.7608 280 1,053 97,934 01/10/24
Wong Alvin F Chief Scientific Off.. Chief Scientific Officer Jan 03 Sell 4.4859 7,733 34,689 98,214 01/05/24
Ludwig Jeffrey Jerome Chief Commercial Off.. Chief Commercial Officer Jan 03 Sell 4.4859 12,956 58,119 99,970 01/05/24
AUERBACH ALAN H President and CEO President and CEO Jan 03 Sell 4.4859 41,396 185,698 6,936,947 01/05/24
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Jan 03 Sell 4.4859 15,682 70,348 128,666 01/05/24
HUNT DOUGLAS M See Remarks See Remarks Jan 03 Sell 4.4859 8,358 37,493 103,319 01/05/24
Wong Alvin F Chief Scientific Off.. Chief Scientific Officer Jul 03 Sell 3.3112 6,938 22,973 105,947 07/06/23
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Jul 03 Sell 3.3112 14,680 48,608 144,348 07/06/23
Ludwig Jeffrey Jerome Chief Commercial Off.. Chief Commercial Officer Jul 03 Sell 3.3112 12,103 40,075 112,926 07/06/23
HUNT DOUGLAS M See Remarks See Remarks Jul 03 Sell 3.3112 7,809 25,857 111,677 07/06/23
AUERBACH ALAN H President and CEO President and CEO Jul 03 Sell 3.3112 60,698 200,983 6,978,343 07/06/23
WILSON TROY EDWARD Director Director Jun 13 Sell 3.45 27,000 93,150 350 06/15/23
MOYES JAY M Director Director Jun 13 Sell 3.45 22,000 75,900 16,322 06/15/23
Stuglik Brian M Director Director Jun 13 Sell 3.46 9,900 34,254 31,958 06/15/23
Senderowicz Adrian Director Director Jun 13 Sell 3.45 27,000 93,150 06/15/23
Dorval Allison Director Director Jun 13 Sell 3.45 10,000 34,500 17,000 06/15/23
MILLER MICHAEL PATRICK Director Director Jun 13 Sell 3.45 13,500 46,575 41,358 06/15/23
AUERBACH ALAN H President and CEO President and CEO Jan 03 Sell 4.1779 27,241 113,810 6,852,638 01/05/23
AUERBACH ALAN H President and CEO President and CEO Dec 02 Sell 4.49780 1,251 5,627 6,311,698 12/06/22
HUNT DOUGLAS M See Remarks See Remarks Dec 02 Sell 4.49780 429 1,930 75,575 12/06/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Dec 02 Sell 4.49780 159 715 110,926 12/06/22
Wong Alvin F Chief Scientific Off.. Chief Scientific Officer Dec 02 Sell 4.49780 514 2,312 58,013 12/06/22
HUNT DOUGLAS M See Remarks See Remarks Nov 02 Sell 2.25 429 965 76,004 11/04/22
AUERBACH ALAN H President and CEO President and CEO Nov 02 Sell 2.25 1,242 2,794 6,312,949 11/04/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Nov 02 Sell 2.25 163 367 111,085 11/04/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Oct 03 Sell 2.3354 165 385 111,248 10/05/22
HUNT DOUGLAS M See Remarks See Remarks Oct 03 Sell 2.3354 435 1,016 76,433 10/05/22
AUERBACH ALAN H President and CEO President and CEO Oct 03 Sell 2.3354 1,260 2,943 6,314,191 10/05/22
MILLER MICHAEL PATRICK Director Director Aug 09 Sell 3.5517 25,000 88,792 54,858 08/10/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Aug 02 Sell 2.89 161 465 111,577 08/04/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Jul 05 Sell 2.6315 9,328 24,547 111,738 08/04/22
HUNT DOUGLAS M See Remarks See Remarks Aug 02 Sell 2.89 429 1,240 77,301 08/04/22
AUERBACH ALAN H President and CEO President and CEO Aug 02 Sell 2.89 1,247 3,604 6,316,705 08/04/22
HUNT DOUGLAS M See Remarks See Remarks Jul 05 Sell 2.6315 3,753 9,876 77,730 07/07/22
AUERBACH ALAN H President and CEO President and CEO Jul 05 Sell 2.6315 26,140 68,787 6,317,952 07/07/22
Ludwig Jeffrey Jerome Chief Commercial Off.. Chief Commercial Officer Jul 05 Sell 2.6315 5,835 15,355 64,625 07/07/22
Wong Alvin F Chief Scientific Off.. Chief Scientific Officer Jul 05 Sell 2.6315 2,920 7,684 58,527 07/07/22
Senderowicz Adrian Director Director Jun 16 Sell 2.6313 27,858 73,303 27,000 06/21/22
WILSON TROY EDWARD Director Director Jun 16 Sell 2.5835 27,858 71,971 27,350 06/21/22
Stuglik Brian M Director Director Jun 16 Sell 2.686 13,000 34,918 41,858 06/21/22
MOYES JAY M Director Director Jun 16 Sell 2.6411 22,858 60,370 38,322 06/21/22
Wong Alvin F Chief Scientific Off.. Chief Scientific Officer Jun 02 Sell 1.9241 587 1,129 61,447 06/06/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Jun 02 Sell 1.9218 162 311 121,066 06/06/22
HUNT DOUGLAS M See Remarks See Remarks Jun 02 Sell 1.9441 417 811 81,483 06/06/22
AUERBACH ALAN H President and CEO President and CEO Jun 02 Sell 1.9441 1,200 2,333 6,344,092 06/06/22
HUNT DOUGLAS M See Remarks See Remarks May 03 Sell 2.3101 438 1,012 81,900 05/05/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer May 03 Sell 2.3401 165 386 121,228 05/04/22
AUERBACH ALAN H President and CEO President and CEO May 03 Sell 2.3201 1,263 2,930 6,345,292 05/04/22
AUERBACH ALAN H President and CEO President and CEO Apr 04 Sell 3.078 1,198 3,687 6,346,555 04/05/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Apr 04 Sell 3.078 206 634 121,393 04/05/22